COMMUNIQUÉS West-GlobeNewswire

IBA et Telix renforcent leur collaboration avec un accord de distribution de la technologie QIS® d’ARTMS
01/10/2026
IBA proposera le système d’irradiation QUANTM ® aux utilisateurs de cyclotrons partout dans le monde, afin d’accélérer la production locale de radio-métaux destinés à la théranostique. Louvain-la-Neuve, Belgique, 01 [...]
Roche’s giredestrant combination significantly improved progression-free survival in ER-positive advanced breast cancer in phase III evERA data published in The New England Journal of Medicine
01/10/2026
Giredestrant plus everolimus reduced the risk of disease progression or death by 44% and 62% in ITT and ESR1 -mutated populations, respectively, versus standard endocrine therapy plus everolimus 1 By targeting [...]
Press Release: Sanofi and Regeneron expand global Alliance with multiple next-generation, long-acting immunology antibodies
01/10/2026
Sanofi and Regeneron expand global Alliance with multiple nex t-generation, long-acting immunology antibodies REGN20423, a clinical-stage long-acting IL-13 monoclonal antibody invented and developed by Regeneron, is [...]
Communiqué de presse : Sanofi et Regeneron élargissent leur Alliance mondiale avec plusieurs anticorps immunologiques de nouvelle génération à action prolongée
01/10/2026
Sanofi et Regeneron élargissent leur Alliance mondiale avec plusieurs anticorps immunologiques de nouvelle génération à action prolongée REGN20423, un anticorps monoclonal anti-IL-13 à action prolongée en phase clinique [...]
Regeneron and Sanofi Expand Global Alliance with Multiple Next-Generation, Long-Acting Immunology Antibodies
01/10/2026
REGN20423, a clinical-stage long-acting IL-13 monoclonal antibody invented and developed by Regeneron, is added to the alliance, along with a long-acting IL-4xIL-13 bispecific and two other long-acting preclinical [...]
National MS Society Launches Campaign to End MS, Declaring for the First Time: Ending MS Is Within Reach
01/10/2026
Five-year, $1 billion campaign to lead the way in ending MS, anchored by the Society's first-ever national research symposium and a landmark day of action in New York City NEW YORK, Oct. 01, 2026 (GLOBE NEWSWIRE) -- The [...]
Adial Pharmaceuticals Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
30/09/2026
GLEN ALLEN, Va., Sept. 30, 2026 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (Nasdaq: ADIL) (“Adial” or the “Company”) today announced that the Company’s Compensation Committee has granted a new employee stock option [...]
Oculis Announces Resignation of Lionel Carnot from Board of Directors
30/09/2026
Oculis Announces Resignation of Lionel Carnot from Board of Directors ZUG, Switzerland, September 30, 2026 -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company [...]
Bright Minds Biosciences to Participate in the 2026 FPWR Research Symposium and PWS Family Conference
30/09/2026
NEW YORK, Sept. 30, 2026 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE: DRUG) (NASDAQ: DRUG) (“ Bright Minds ” or the “ Company ”), a clinical stage biotechnology company focused on developing highly selective [...]
Immix Biopharma Announces Closing of $125 Million Underwritten Offering of Common Stock
30/09/2026
– Financing includes leading U.S. biotechnology institutional investors and mutual funds – LOS ANGELES, CA, Sept. 30, 2026 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “we” or “us” or “IMMX”), a [...]
Oculis Announces Resignation of Lionel Carnot from Board of Directors
30/09/2026
ZUG, Switzerland, September 30, 2026 -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company focused on breakthrough innovations to address significant unmet [...]
Standard BioTools Provides Update on Sale of Mass Cytometry Business
30/09/2026
Standard BioTools Enters into New Purchase Agreement with Element Biosystems, a Subsidiary of GMT Venture, After Determining GMT Venture’s Unsolicited Acquisition Proposal as Superior BOSTON, Mass., Sept. 30, 2026 ( [...]
TAPI (Technology & API Services) Names Serge Rogasik CEO to lead next chapter of growth and competitiveness
30/09/2026
TEL AVIV, Israel, Sept. 30, 2026 (GLOBE NEWSWIRE) -- TAPI (Technology & API Services) today announced the appointment of Serge Rogasik as its Chief Executive Officer. Mr. Rogasik will lead a global business that [...]
Tevogen Regains Compliance with Nasdaq Global Market Continued Listing Requirements
30/09/2026
Both previously disclosed Nasdaq compliance matters are now closed WARREN, N.J., Sept. 30, 2026 (GLOBE NEWSWIRE) -- Tevogen Inc. (“Tevogen” or the “Company”) (Nasdaq: TVGN ), an integrated healthcare enterprise [...]
Pliant Therapeutics Appoints David Raben, M.D., as Chief Medical Officer
30/09/2026
Leader in targeted immuno-oncology drug development brings three decades of academic and biopharmaceutical oncology expertise SOUTH SAN FRANCISCO, Calif., Sept. 30, 2026 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. ( [...]
Abivax to Present Data on Obefazimod at United European Gastroenterology (UEG) Week 2026
30/09/2026
Abivax to Present Data on Obefazimod at United European Gastroenterology (UEG) Week 2026 Four oral presentations and three posters build upon Phase 3 ABTECT Maintenance and Induction programs in ulcerative colitis, long [...]
Abivax présentera des données sur l’obéfazimod lors de l’United European Gastroenterology (UEG) Week 2026
30/09/2026
Abivax présentera des données sur l’obéfazimod lors de l’United European Gastroenterology (UEG) Week 2026 Quatre présentations orales et trois posters s’appuient sur les données issues des programmes de maintenance et d [...]
Atsena Presents Positive 18-Month Results from Part A of the Phase 1/2/3 LIGHTHOUSE Trial Evaluating ATSN-201 in Patients with X-linked Retinoschisis
30/09/2026
18-month results from Part A of LIGHTHOUSE Trial reinforce ATSN-201’s favorable safety profile and durable structural and functional benefits in patients with X-linked retinoschisis Pivotal Part C cohort enrollment [...]
Longeveron to Participate in Three Longevity/Aging Investment Conferences
30/09/2026
New Data Analysis from Phase 2a Clinical Trial in Alzheimer’s Disease (AD) Indicating That Laromestrocel Treatment May Reduce Neuroinflammation in the Brain, A Core Driver of AD Pathogenesis, Published on medRxiv MIAMI [...]

Pages